Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

DaVita HealthCare Partners Inc Add to portfolio

INX:DVA, May 20, 11:20 UTC

Latest INX:DVA News

Filter your feed

Apply Filter

Today


News

Financial Analysis: Caladrius Biosciences (CLBS) & DaVita (DVA)

DVA

DaVita (NYSE: DVA) and Caladrius Biosciences (NASDAQ:CLBS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings. Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter. Given Caladrius Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Caladrius Biosciences is more favorable than DaVita.

Read Full Details

Topics:
  • Business
  • Health
News

Cincinnati Financial Has Increased Its Valero Energy (VLO) Holding by $3.46 Million; Stock Value Rose; Davita (Put) (DVA) Shareholder Verition Fund Management Has Upped Its Stake by $360,000 as Share Price Declined

DVA VLO +1 more DVA VLO CINF

Valiant Capital Management LP Has Trimmed Apple (AAPL) Position by $499.67 Million as Shares Declined; As Valero Energy (VLO) Share Price Rose, Cincinnati Financial Has Increased by $3.46 Million Its Holding. The hedge fund run by Christopher R. Hansen held 443,400 shares of the computer manufacturing company at the end of 2017Q4, valued at $75.04 million, down from 3.40M at the end of the previous reported quarter. Another trade for 15,653 shares valued at $2.90M was sold by WILLIAMS JEFFREY E. LEVINSON ARTHUR D sold $6.51M worth of stock. More notable recent Apple Inc. (NASDAQ:AAPL) news were published by: Livetradingnews.com which released: “Apple Inc. (NASDAQ:AAPL) Stock Consolidating” on May 18, 2018, also Fool.com with their article: “Why Buffett Keeps Buying Apple” published on May 19, 2018, Fool.com published: “Why It’s Not Smart to Bet Against Apple’s iPhone Business” on May 17, 2018.

Read Full Details

Topics:
  • Business
  • Financial

Friday, May 18


News

Analyzing Catasys (CATS) & DaVita (DVA)

DVA

Catasys (NASDAQ: CATS) and DaVita (NYSE:DVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter. Comparatively, 89.2% of DaVita shares are held by institutional investors.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, May 16


News

Somewhat Positive Media Coverage Somewhat Unlikely to Affect DaVita (NYSE:DVA) Share Price

DVA

The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern also assigned headlines about the company an impact score of 47.1269932428871 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future. Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. Somewhat Favorable News Coverage Somewhat Unlikely to Affect DaVita (NYSE:DVA) Share Price – The Ledger Gazette.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, May 15


News

Comparing DaVita (DVA) and Caladrius Biosciences (CLBS)

DVA

Caladrius Biosciences (NASDAQ: CLBS) and DaVita (NYSE:DVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Caladrius Biosciences is more favorable than DaVita.

Read Full Details

Topics:
  • Business
  • Health

Sunday, May 13


News

DaVita (DVA) vs. Caladrius Biosciences (CLBS) Financial Contrast – Macon Daily

DVA

DaVita (DVA) vs. Caladrius Biosciences (CLBS) Financial Contrast – Macon Daily. DaVita (NYSE: DVA) and Caladrius Biosciences (NASDAQ:CLBS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk. Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.

Read Full Details

Topics:
  • Business
  • Health

Saturday, May 12


News

DaVita (DVA) Announces Earnings Results, Beats Expectations By $0.13 EPS – Macon Daily

DVA

DaVita (DVA) Issues Earnings Results, Beats Expectations By $0.13 EPS – The Lincolnian Online. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.13, Bloomberg Earnings reports. Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and two have issued a strong buy rating to the stock.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, May 08


News

DaVita (DVA) Beats Q1 Earnings Estimates, Reiterates View - May 8, 2018

DVA

Adjusted Kidney Care operating income was $411 million, up 8.2% year over year. As an operating division of DaVita, DaVita Kidney Care focuses on setting worldwide standards for clinical, social and operational practices in kidney care. The company’s patient care costs were up approximately 25 cents per treatment compared with the last reported quarter. For investors’ notice, the company’s major segment — DaVita Medical Group (“DMG”) — is on track for divestment to Optum, a subsidiary of UnitedHealth Group Inc. A few better-ranked stocks in the broader medical space, which reported solid earnings this season, are Baxter International Inc. BAX, Varian Medical Systems, Inc. VAR and Intuitive Surgical, Inc. ISRG. While Intuitive Surgical and Varian sport a Zacks Rank #1 (Strong Buy), Baxter carries a Zacks Rank #2 (Buy). Baxter reported first-quarter 2018 adjusted earnings per share of 70 cents, which beat the Zacks Consensus Estimate by 12.9% and improved from the year-ago quarter’s figure of 58 cents.

Read Full Details

Topics:
  • Business
  • Financial

Monday, May 07


News

Comparing Davita (DVA) and Catasys (CATS) – registrarjournal.com

DVA

Davita (NYSE: DVA) and Catasys (NASDAQ:CATS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability. Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter. This table compares Davita and Catasys’ net margins, return on equity and return on assets.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Health Care Heroes: DaVita Celebrates its Kidney Care Nurses During National Nurses Week

DVA

DENVER, May 7, 2018 /PRNewswire/ -- DaVita Kidney Care, a division of DaVita Inc. (DVA), a leading provider of kidney care services in the United States, today kicked off National Nurses Week by thanking its more than 18,000 nurses for the integral role each plays in helping patients with kidney disease have a better quality of life. Kidney care nurses spend a lot of time with their patients, as many patients receive in-center hemodialysis three times a week for up to four hours per treatment. "Not only do DaVita nurses deliver quality care that helps maintain our position as a clinical outcomes leader, but we listen to patients, seek to understand each personally and do our best to support patients through both challenging and joyful times," said Mandy Hale, RN, vice president of nursing for DaVita Kidney Care. DaVita offers eligible nurses a number of opportunities to engage in life-long learning by providing benefits such as tuition reimbursement and all-expense-paid attendance at professional nursing conferences through its LeaRN award.

Read Full Details

Topics:
  • Business
  • Health
  • Politics
  • Science